SCHEMBL24974708

SCHEMBL24974708

CCCC(=O)NC1(C)CCCCCCCCCCCCCCC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.49
HDAC3 O15379 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC2 Q92769 1/20 0.41
HDAC8 Q9BY41 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
CTSD P07339 1/20 0.40
EPHX2 P34913 3/20 0.35
SPHK1 Q9NYA1 1/20 0.35
NPC1 O15118 1/20 0.35
TP53 P04637 1/20 0.35
RAB9A P51151 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
TSHR P16473 1/20 0.34
CASP2 P42575 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
ALDH1A1 P00352 2/20 0.34
KDM4E B2RXH2 1/20 0.33
MAPT P10636 1/20 0.33
DPP4 P27487 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8689464 1.00 LMNA (0.49) LMNAHDAC3HDAC1HDAC2HDAC8
SCHEMBL17033150 0.90 HDAC3 (0.46) LMNAHDAC3HDAC1HDAC2HDAC8
SCHEMBL13146756 0.86 EPHX2 (0.45) LMNAEPHX2SPHK1TP53SMN1; SMN2
SCHEMBL8684589 0.83 ANO1 (0.37) LMNAHDAC3HDAC1HDAC2HDAC6
SCHEMBL12315745 0.82 PHF8 (0.45) LMNAEPHX2TP53SMN1; SMN2TSHR
SCHEMBL8446598 0.82 EPHX2 (0.33) LMNAHDAC3HDAC1HDAC2HDAC6
SCHEMBL18793892 0.81 CYP2C9 (0.35) LMNAL3MBTL1ALDH1A1KDM4EMAPT
SCHEMBL3001083 0.81 EPHX2 (0.37) LMNAHDAC3HDAC1HDAC2HDAC8
SCHEMBL12316377 0.79 EPHX2 (0.42) LMNAHDAC3HDAC1HDAC8HDAC6
SCHEMBL5143779 0.79 DPP4 (0.35) LMNAHDAC3HDAC1HDAC2HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11572370-B2 CD16A binding agents and uses thereof BIOHAVEN THERAPEUTICS LTD. (US) 2023-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11572370-B2 CD16A binding agents and uses thereof FCGR1A, FCGR2A, FCGR3B LMNA 2855/4885HDAC3 2964/4885HDAC1 2698/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.